GHRH and neoplasm: Previous studies have shown that both early and latest series of GHRH antagonists, including those from the MIAMI (MIA) class, suppress cell proliferation and tumor growth in vitro and in vivo in experimental SCLC and NSCLC by hampering proliferative and survival pathways, promoting apoptosis and reactive oxygen species (ROS) production, and reducing the expression of angiogenic growth factors and their receptors [13,14,15,16].